MA50518A - Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 - Google Patents

Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Info

Publication number
MA50518A
MA50518A MA050518A MA50518A MA50518A MA 50518 A MA50518 A MA 50518A MA 050518 A MA050518 A MA 050518A MA 50518 A MA50518 A MA 50518A MA 50518 A MA50518 A MA 50518A
Authority
MA
Morocco
Prior art keywords
insm1
predicting
expression
therapeutic effect
lsd1 inhibitor
Prior art date
Application number
MA050518A
Other languages
English (en)
Inventor
Ryo Hatanaka
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA50518A publication Critical patent/MA50518A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
MA050518A 2017-05-31 2018-05-30 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1 MA50518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017108422 2017-05-31

Publications (1)

Publication Number Publication Date
MA50518A true MA50518A (fr) 2020-09-09

Family

ID=64454631

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050518A MA50518A (fr) 2017-05-31 2018-05-30 Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1

Country Status (8)

Country Link
US (1) US20200190175A1 (fr)
EP (1) EP3633380A4 (fr)
JP (1) JP6915056B2 (fr)
KR (1) KR102291852B1 (fr)
AU (1) AU2018276611B2 (fr)
MA (1) MA50518A (fr)
TW (1) TWI749235B (fr)
WO (1) WO2018221555A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6510068B2 (ja) 2015-11-27 2019-05-08 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
MX2019014104A (es) 2017-05-26 2020-02-07 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
FI3632443T3 (fi) 2017-05-26 2023-08-23 Taiho Pharmaceutical Co Ltd Kasvainkasvua ehkäisevän vaikutuksen tehostaja, jossa käytetään bifenyyliyhdistettä
MX2022005812A (es) * 2019-11-13 2022-08-16 Taiho Pharmaceutical Co Ltd Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225049B1 (en) * 1992-06-17 2001-05-01 The United States Of America As Represented By The Department Of Health And Human Services Human insulinoma-associated cDNA
WO2010048123A2 (fr) * 2008-10-20 2010-04-29 Eckhardt S Gail Marqueurs biologiques prédictifs d'une réponse anticancéreuse à des inhibiteurs de récepteur kinase de facteur de croissance 1 de type insuline
WO2010120966A1 (fr) * 2009-04-17 2010-10-21 Osi Pharmaceuticals, Inc. Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de récepteur kinase de facteur de croissance épidermique
US9181198B2 (en) * 2010-07-29 2015-11-10 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
EP2688568B1 (fr) 2011-03-25 2019-06-19 Glaxosmithkline Intellectual Property (No. 2) Limited Cyclopropylamines en tant qu'inhibiteurs de lsd1
ES2642170T3 (es) * 2011-05-16 2017-11-15 Taiho Pharmaceutical Co., Ltd. Método para seleccionar la quimioterapia para un paciente con cáncer gástrico utilizando combinación de fármacos de tegafur, gimeracilo y oteracilo potásico e inhibidor de EGFR
BR112016002496B1 (pt) * 2013-08-06 2022-07-12 Imago Biosciences Inc. Composto e composição farmacêutica
HUE061252T2 (hu) 2013-12-11 2023-05-28 Celgene Quanticel Res Inc Lizinspecifikus demetiláz-1 inhibítorok
RS62874B1 (sr) 2014-05-01 2022-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
WO2017013061A1 (fr) * 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarqueurs associés à des inhibiteurs de lsd1 et utilisations de ceux-ci
CN105233292B (zh) * 2015-10-19 2018-03-13 中国科学院北京基因组研究所 Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途
JP6510068B2 (ja) * 2015-11-27 2019-05-08 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩
MX2019014104A (es) * 2017-05-26 2020-02-07 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
WO2019075327A1 (fr) * 2017-10-12 2019-04-18 Dana-Farber Cancer Institute, Inc. Traitement du carcinome à cellules de merkel

Also Published As

Publication number Publication date
AU2018276611A1 (en) 2020-01-16
JPWO2018221555A1 (ja) 2020-05-21
KR102291852B1 (ko) 2021-08-23
TWI749235B (zh) 2021-12-11
RU2019144056A3 (fr) 2021-07-02
EP3633380A4 (fr) 2021-02-24
KR20200007975A (ko) 2020-01-22
TW201907162A (zh) 2019-02-16
WO2018221555A1 (fr) 2018-12-06
US20200190175A1 (en) 2020-06-18
AU2018276611B2 (en) 2022-01-06
EP3633380A1 (fr) 2020-04-08
RU2019144056A (ru) 2021-07-02
JP6915056B2 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
CA193082S (en) Point of sale device
IL262488A (en) lsdi inhibitor formulations
MA54550A (fr) Inhibiteurs de kif18a
ZA202000934B (en) Device and method of constructing shoes
MA50518A (fr) Méthode de prédiction de l'effet thérapeutique d'un inhibiteur de lsd1 en fonction de l'expression d'insm1
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
EP3114109A4 (fr) Inhibiteurs de la déméthylase (lsd1) spécifique d'une lysine d'histone et d'histones désacétylases (hdac)
MA51616A (fr) Inhibiteurs d'adn-pk
MA49908A (fr) Composés inhibant la protéine mcl-1
FR3052891B1 (fr) Procede d'estimation du facteur d'intensite des contraintes et procede de calcul de duree de vie associe
MA52812A (fr) Inhibiteurs de sarm1
MA53287A (fr) Inhibiteurs de prmt5
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3624804A4 (fr) Inhibiteurs des histone désacétylases (hdac)
MA47305A (fr) Inhibiteurs bicycliques d'histone désacétylase
MA49006A (fr) Inhibiteurs d'ip6k
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
MA51611A (fr) Inhibiteurs de pi4kiiibêta
GB201700711D0 (en) Application of an optical effect
MA49839A (fr) Inhibiteurs bicycliques d'histone désacétylase
UA38744S (uk) Монітор
MA52809A (fr) Inhibiteurs de sarm1
MA52813A (fr) Inhibiteurs de sarm1
MA53128A (fr) Inhibiteurs bicycliques de l'histone désacétylase